These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29116597)

  • 1. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.
    Gomez EV; Bishop JL; Jackson K; Muram TM; Phillips D
    BioDrugs; 2017 Dec; 31(6):545-554. PubMed ID: 29116597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects.
    Tay L; Leon F; Vratsanos G; Raymond R; Corbo M
    Arthritis Res Ther; 2007; 9(2):R38. PubMed ID: 17425783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.
    Brodmerkel C; Wadman E; Langley RG; Papp KA; Bourcier M; Poulin Y; Ho V; Guenther L; Kunynetz R; Nigen S; Vender R; Wasel N; Hsu MC; Szapary P
    J Drugs Dermatol; 2013 Oct; 12(10):1122-9. PubMed ID: 24085047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
    Winthrop KL; Korman N; Abramovits W; Rottinghaus ST; Tan H; Gardner A; Mukwaya G; Kaur M; Valdez H
    J Am Acad Dermatol; 2018 Jun; 78(6):1149-1155.e1. PubMed ID: 29080806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Booy R
    Vaccine; 2016 Nov; 34(48):5929-5937. PubMed ID: 27780630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
    Chatham WW; Wallace DJ; Stohl W; Latinis KM; Manzi S; McCune WJ; Tegzová D; McKay JD; Avila-Armengol HE; Utset TO; Zhong ZJ; Hough DR; Freimuth WW; Migone TS;
    J Rheumatol; 2012 Aug; 39(8):1632-40. PubMed ID: 22707609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
    Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
    Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
    Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
    Guenther L; Warren RB; Cather JC; Sofen H; Poulin Y; Lebwohl M; Terui T; Potts Bleakman A; Zhu B; Burge R; Reich K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1867-1875. PubMed ID: 28573743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
    Buttery JP; Riddell A; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Harnden A; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
    JAMA; 2005 Apr; 293(14):1751-8. PubMed ID: 15827314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
    Blauvelt A; Muram TM; See K; Mallinckrodt CH; Crowley JJ; van de Kerkhof P
    J Dermatolog Treat; 2018 May; 29(3):220-229. PubMed ID: 28792259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.